NTLA
Price:
$14.3
Market Cap:
$1.46B
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Reg...[Read more]
Industry
Biotechnology
IPO Date
2016-05-06
Stock Exchange
NASDAQ
Ticker
NTLA
According to Intellia Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -51.97%. This represents a change of 298.32% compared to the average of -13.05% of the last 4 quarters.
The mean historical ROE of Intellia Therapeutics, Inc. over the last ten years is -44.44%. The current -51.97% ROE has changed 16.94% with respect to the historical average. Over the past ten years (40 quarters), NTLA's ROE was at its highest in in the March 2016 quarter at 24.64%. The ROE was at its lowest in in the December 2014 quarter at -95.38%.
Average
-44.44%
Median
-27.84%
Minimum
-189.12%
Maximum
-15.08%
Discovering the peaks and valleys of Intellia Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 58.91%
Maximum Annual ROE = -15.08%
Minimum Annual Increase = -90.27%
Minimum Annual ROE = -189.12%
Year | ROE | Change |
---|---|---|
2023 | -45.82% | 15.49% |
2022 | -39.67% | 58.91% |
2021 | -24.97% | 4.80% |
2020 | -23.82% | -30.64% |
2019 | -34.35% | 11.85% |
2018 | -30.71% | 36.66% |
2017 | -22.47% | 49.05% |
2016 | -15.08% | -18.09% |
2015 | -18.41% | -90.27% |
The current ROE of Intellia Therapeutics, Inc. (NTLA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-36.82%
5-year avg
-33.73%
10-year avg
-44.44%
Intellia Therapeutics, Inc.’s ROE is greater than Editas Medicine, Inc. (-80.13%), greater than Caribou Biosciences, Inc. (-45.46%), greater than CRISPR Therapeutics AG (-12.15%), greater than Verve Therapeutics, Inc. (-35.23%), greater than Beam Therapeutics Inc. (-16.22%), greater than Fate Therapeutics, Inc. (-45.88%), greater than Vertex Pharmaceuticals Incorporated (-2.88%), greater than Ginkgo Bioworks Holdings, Inc. (-70.11%), greater than Prime Medicine, Inc. (-114.95%), greater than Sana Biotechnology, Inc. (-94.47%),
Company | ROE | Market cap |
---|---|---|
-80.13% | $201.42M | |
-45.46% | $182.92M | |
-12.15% | $4.09B | |
-35.23% | $410.62M | |
-16.22% | $2.07B | |
-45.88% | $260.82M | |
-2.88% | $116.14B | |
-70.11% | $412.70M | |
-114.95% | $419.71M | |
-94.47% | $582.73M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Intellia Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Intellia Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Intellia Therapeutics, Inc.'s ROE?
How is the ROE calculated for Intellia Therapeutics, Inc. (NTLA)?
What is the highest ROE for Intellia Therapeutics, Inc. (NTLA)?
What is the 3-year average ROE for Intellia Therapeutics, Inc. (NTLA)?
What is the 5-year average ROE for Intellia Therapeutics, Inc. (NTLA)?
How does the current ROE for Intellia Therapeutics, Inc. (NTLA) compare to its historical average?